MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aquestive Therapeutics, Inc. - Common Stock (NQ:AQST)

4.110 +0.270 (+7.03%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aquestive Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm™ (epinephrine) Sublingual Film at the CFAAR Food Allergy Summit
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aquestive Therapeutics Announces FDA Acceptance of New Drug Application and PDUFA Date for Anaphylm™ for the Treatment of Severe Allergic Reactions
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For May 12, 2025 ↗
 
Via Benzinga
News headline image
Aquestive Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Uncovering Potential: Aquestive Therapeutics's Earnings Preview ↗
 
Via Benzinga
News headline image
Aquestive Therapeutics to Participate in Citizens Life Sciences Conference
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aquestive Therapeutics to Report First Quarter 2025 Financial Results and Recent Business Highlights on May 12 and Host Conference Call on May 13 at 8:00 a.m. ET
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aquestive Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aquestive Therapeutics Concludes FDA Application For Allergy Drug With Encouraging Pediatric Trial Data ↗
Aquestive's Anaphylm sublingual film met key pediatric study goals, supporting its NDA submission to the FDA for potential approval in 2025. 
Via Benzinga
News headline image
Aquestive Therapeutics Announces Positive Topline PK Results from its Pediatric Study and Completes the NDA Submission for Anaphylm™ (epinephrine) Sublingual Film
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aquestive Therapeutics Stock Dips After-Hours On Q4 Miss — Retail Eyes Silver Linings ↗
Stocktwits users are viewing the company's cash position, expectations for a late 2026 Anaphylm launch, and an upcoming trial as positive signals. 
Via Stocktwits
News headline image
Curious about the stocks that are showing activity after the closing bell on Wednesday? ↗
As the regular session of the US market on Wednesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment. 
Via Chartmill
News headline image
Aquestive Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aquestive Therapeutics to Participate in Two Upcoming Conferences in March
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For March 5, 2025 ↗
 
Via Benzinga
News headline image
Aquestive Therapeutics to Report Fourth Quarter 2024 Financial Results and Recent Business Highlights on March 5 and Host Conference Call on March 6 at 8:00 a.m. ET
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aquestive Therapeutics to Present New Findings on Anaphylm™ (Epinephrine Sublingual Film) at the 2025 AAAAI Annual Meeting
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aquestive Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Conference
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aquestive Therapeutics Provides Business Update and Outlines Key 2025 Objectives
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aquestive Therapeutics Receives U.S. FDA Orphan Drug Exclusivity for Libervant® (diazepam) Buccal Film in Pediatric Patients with Seizure Clusters Ages Two to Five
U.S. FDA Orphan Drug exclusivity provides seven years of market exclusivity for Libervant® (diazepam) Buccal Film in the United States for the treatment of seizure clusters in patients ages 2 to 5 
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Developer Of EpiPen Alternative Aquestive Stock Undervalued Despite Strong Clinical Data, Analyst Sees Huge Upside ↗
Cantor initiates coverage on Aquestive Therapeutics, highlighting Anaphylm's potential to disrupt the epinephrine auto-injector market with 200% upside. 
Via Benzinga
News headline image
Aquestive Therapeutics Announces Positive FDA Feedback and Reaffirms NDA Submission Guidance for Anaphylm™ (epinephrine) Sublingual Film
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aquestive Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aquestive Therapeutics to Present Subsequent Analysis of Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Demonstrating Comparable PK and PD Data to Epinephrine Injection Regardless of Variable Placement or Intraoral Movement at American College
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aquestive Therapeutics Announces Positive Topline Results from Oral Allergy Syndrome (OAS) Challenge Study for Anaphylm™ (epinephrine) Sublingual Film
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aquestive Therapeutics to Report Third Quarter 2024 Financial Results and Recent Business Highlights on November 4 and Host Conference Call on November 5 at 8:00 a.m. ET
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Optimism Around Aquestive As it Moves Forward With Severe Allergy, Baldness Candidate ↗
Aquestive Therapeutics hosted a virtual investor day, announcing advancements in Anaphylm and AQST-108. The company aims for FDA meetings in late 2024, targeting a 2025 NDA submission, while HC... 
Via Benzinga
News headline image
Aquestive Therapeutics Spotlights its Innovative Epinephrine Delivery Pipeline at Virtual Investor Day
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story